TY - JOUR
T1 - Therapy of Nonnecrotizing Anterior Scleritis with Subconjunctival Corticosteroid Injection
AU - Tu, Elmer Y.
AU - Culbertson, William W.
AU - Pflugfelder, Stephen C.
AU - Huang, Andrew
AU - Chodosh, James C.
N1 - Funding Information:
Originally received: November 14, 1993. Revision accepted: December 31, 1994. From the Department ofOphthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami. Supported in part by a grant from Research to Prevent Blindness, Inc, New York, New York. Reprint requests to Elmer Y. Tu, MD, University of Texas Health Science Center-San Antonio, Department of Ophthalmology, 7703 floyd Curl Dr, San Antonio, TX 78284-6230.
PY - 1995
Y1 - 1995
N2 - Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival Corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%)responded poorly. Nine patients (45%)required no further therapy. Average symptom-free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and jor perforation and should be considered as adjunctive therapy in localized disease.
AB - Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival Corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%)responded poorly. Nine patients (45%)required no further therapy. Average symptom-free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and jor perforation and should be considered as adjunctive therapy in localized disease.
UR - http://www.scopus.com/inward/record.url?scp=0029026424&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(95)30963-3
DO - 10.1016/S0161-6420(95)30963-3
M3 - Article
C2 - 7777270
AN - SCOPUS:0029026424
SN - 0161-6420
VL - 102
SP - 718
EP - 724
JO - Ophthalmology
JF - Ophthalmology
IS - 5
ER -